title: Proceed with caution: off-label ketamine treatment for major depressive disorder.
abstract: Ketamine offers a promising new option for the treatment of depression, but its increasing off-label use is ethically and clinically inappropriate at the moment.
authors.affiliation: Department of Medical Ethics & Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, sistid@mail.med.upenn.edu.
authors.forename: Dominic
authors.initials: D
authors.lastname: Sisti
authors.forename: Andrea G
authors.initials: AG
authors.lastname: Segal
authors.forename: Michael E
authors.initials: ME
authors.lastname: Thase
mesh_terms: D003865:Major Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D007649:Ketamine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D056687:Off-Label Use / Q000941:ethics / Q000592:standards*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*
chemical_list: D016194:Receptors, N-Methyl-D-Aspartate; D007649:Ketamine